Heart Transplant Rejection
20
4
7
8
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 20 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (20)
Surveillance HeartCare® Outcomes Registry
A National Swedish Study Evaluating Dd-cfDNA for as a Diagnostic Biomarker for Rejection Surveillence in Heart Transplantation
Trifecta-Heart cfDNA-MMDx Study
TTV Viral Load in Heart Transplant Recipients
Mobile Video Directly Observed Therapy (DOT) for Immunosuppression Medication Adherence in Adolescent Heart Transplant Recipients
IMR-Heart Trasplant Study
Phase II Study Evaluating the Efficacy of Tacrolimus Extended Release Tablets to Twice Daily Tacrolimus Dosing Regimen
Prospera Test Evaluation in Cardiac Transplant (ProTECT)
Extracorporeal Photopheresis and Early Cardiac Graft Vasculopathy
Cardiac Transplant Metabolomics With and Without Rejection
Molecular Diagnosis of Heart Allograft Rejection Using Intra-Graft Targeted Gene Expression Profiling.
Biomarkers for Diagnosis, Prognosis, and Targeted Therapy After Heart Transplantation
Research on Patients With Heart Transplantation
MuLtimodality EvaluatiOn of aNtibody mEdiated Damage in Heart Transplantation (LEONE-HT)
The TOGETHER Project - Heart
A New Biomarker for the Non-invasive Diagnosis of Rejection After Heart Transplantation
Donor-derived Cell Free DNA as a New Biomarker in Cardiac Acute Rejection
HEart trAnsplantation Registry of piTie-Salpetriere University Hospital
Cardiac Magnetic Resonance Imaging (CMRI) for Detection of Cardiac Transplant Rejection
Heartsbreath Test for Heart Transplant Rejection